Tejas Vyas's questions to Regenxbio Inc (RGNX) leadership • Q1 2025
Question
Speaking for Ellie Merle, Tejas Vyas from UBS asked for clarification on the upcoming RGX-202 functional data release, details on the commercial manufacturing process, and whether Phase I/II patients would be included in the pivotal dataset.
Answer
President and CEO Curran Simpson clarified the RGX-202 data update will be a press release in 1H 2025, not at ASGCT, focusing on dose level 2 patients. He confirmed commercial manufacturing will use the same validated process as the pivotal trial and that qualifying Phase I/II patients will be included in the BLA filing dataset.